Beyond taxanes: the next generation of microtubule-targeting agents - Wikidata - awgldk - TriplyDB

Beyond taxanes: the next generation of microtubule-targeting agents

Beyond taxanes: the next generation of microtubule-targeting agents

http://www.wikidata.org/entity/Q26865369

about

A novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cells Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial Enzymatic synthesis of epothilone A glycosides Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment Tubulin inhibitors: a patent review.Etirinotecan pegol for the treatment of breast cancer.Merkel cell polyomavirus small T antigen mediates microtubule destabilization to promote cell motility and migration.Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases.Analysis of epothilone B-induced cell death in normal ovarian cells.Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin.Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).

P2860

Q27302772-1F73EF50-DB13-48B0-813C-711162EB5CB2 Q28534786-0F778BF3-B34E-4D2C-8543-394C1EDC38D2 Q33737744-CC5C99C3-FC7F-4618-9C51-3D8CFAEA4AA7 Q36020972-63E3E756-1EA6-497A-8496-58A1B8C894C4 Q38169237-0E8F5B8F-4406-4730-872B-460E8737FE30 Q38735361-D1E74F65-F3C4-4AC3-A869-82F27DB444CD Q38947336-36A14620-B614-4AF4-8D04-BC0D0B7FC228 Q38999750-1DF8DDA5-03E3-4BDD-A829-414E0D36038B Q39108561-FB11E480-A07C-4ED4-A9C7-4EC7701C3EAF Q41994470-E00D1651-6DBF-41BA-A0EF-672868DC2892 Q50045537-265412EF-A7FB-42A5-BF27-CC5F0464B20C

P2860

Beyond taxanes: the next generation of microtubule-targeting agents

http://www.wikidata.org/entity/Q26865369

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Beyond taxanes: the next generation of microtubule-targeting agents

@ast

Beyond taxanes: the next generation of microtubule-targeting agents

@en

Beyond taxanes: the next generation of microtubule-targeting agents

@nl

type

label

Beyond taxanes: the next generation of microtubule-targeting agents

@ast

Beyond taxanes: the next generation of microtubule-targeting agents

@en

Beyond taxanes: the next generation of microtubule-targeting agents

@nl

prefLabel

Beyond taxanes: the next generation of microtubule-targeting agents

@ast

Beyond taxanes: the next generation of microtubule-targeting agents

@en

Beyond taxanes: the next generation of microtubule-targeting agents

@nl

P1433

Q26865369-6FF5CBF2-CBDA-447E-AEB3-15D344A15824

P1476

Q26865369-CFD9D0F3-F281-45DA-A0C9-DE18BDC84F54

P2093

Q26865369-A5DC548A-12F4-4D85-AD4D-EE84EEC13FD6

P2860

Q26865369-008DD6DD-1CEC-46B3-AF81-4314FF721CBD

Q26865369-0A78504F-F1DC-423C-AB27-1450B2F5D6E7

Q26865369-1061D88E-9657-4C8E-A0C9-8666AD5AA7D4

Q26865369-1938F0A9-37D5-42A4-B8AA-A2CB7FB03DF5

Q26865369-1AFBACDC-DAFE-4739-ACEB-094D903C1846

Q26865369-1BCF0BDB-1801-40A4-A06A-4B1279ABE999

Q26865369-1CB62FC9-777D-4EE9-8F8E-8D916EDA0360

Q26865369-1EA62EC6-E1A1-48DC-AB4D-5EB72D4C3164

Q26865369-1F246E30-08C4-4E52-9B22-A3107141E12A

Q26865369-241B6FC4-9F89-4B1B-8FB4-A0D46DB878AE

P2888

Q26865369-48964C18-8546-4788-AEBC-5F6204996795

P304

Q26865369-BED39ADE-A0F8-4DE2-AC02-68C9FA12A6B8

P31

Q26865369-2108D58E-7C6A-4EE7-AF23-E6E53A2DE2B5

Q26865369-4D18863F-61CE-4520-A571-51F1DC3C0EEB

P356

Q26865369-A7788B56-E751-47F1-9478-A340E7D503B2

P407

Q26865369-BE2BE9A1-F292-4965-92A1-C9F3591CA847

P433

Q26865369-BC1B94A9-5097-4B56-9CEF-516D2E4BFDFD

P478

Q26865369-5BA52125-6A58-4D49-B8F1-392BAD16E6A7

P50

Q26865369-BF152CCA-35AE-44B8-9A4C-733C0CE1B66E

P577

Q26865369-561B8285-7B97-401F-A36A-25178E48BCA8

Q26865369-C8593629-8EB5-4C53-AD4A-A2CB2B6B495A

P5875

Q26865369-FDD6E240-08AC-4827-85FF-7968EFE65AC1

P6179

Q26865369-86968168-279F-4FF2-99E0-9F7687FBEC2D

P698

Q26865369-614DC1B6-8DDC-41B5-9EBA-07B9FF4154E0

P921

Q26865369-0DF3E915-AB57-4E7F-A1AF-C215379BF88A

Q26865369-9E0BED6B-CB5A-4E64-B4D5-6DB82B2B96E2

Q26865369-F4B7EAE2-BE77-4D53-9695-DACB13AA835B

Q26865369-FBAFD0EC-C098-4661-84A0-EC053C9D42AF

P932

Q26865369-D396DA8C-79E7-454F-9C13-D0A523520A03

P356

S10549-011-1875-6

P1433

Breast Cancer Research and Treatment

P1476

Beyond taxanes: the next generation of microtubule-targeting agents

@en

P2093

Maria Vidal

http://www.w3.org/2001/XMLSchema#string

P2860

Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Detecting an overall survival benefit that is derived from progression-free survival

P2888

s10549-011-1875-6

P304

821-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-011-1875-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51825076

http://www.w3.org/2001/XMLSchema#string

P6179

1002791362

http://www.w3.org/2001/XMLSchema#string

P698

22113255

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

breast neoplasm

P932

3387492

http://www.w3.org/2001/XMLSchema#string